DNMT3B gene amplification predicts resistance to DNA demethylating drugs

Genes Chromosomes and Cancer

Volumn 50, Issue 7, 2011, Pages 527-534

  Simó Riudalbas, Laia ^a   Melo, Sónia A ^a   Esteller, Manel ^a,b,c  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; DNA METHYLTRANSFERASE 3B; MESSENGER RNA; SGI 1027; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL VIABILITY; DRUG EFFECT; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; AZACITIDINE; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; RNA, MESSENGER;

EID: 79955648677     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20877     Document Type: Article

References (40)

1. Albertson DG. 2006. Gene amplification in cancer. Trends Genet 22: 447-455.
2. Alitalo K, Schwab M, Lin CC, Varmus HE, Bishop JM. 1983. Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci USA 80: 1707-1711.
3. Beaulieu N, Morin S, Chute IC, Robert MF, Nguyen H, MacLeod AR. 2002. An essential role for DNA methyltransferase DNMT3B in cancer cell survival. J Biol Chem 277: 28176-28181.
4. Berdasco M, Esteller M. 2010. Aberrant epigenetic landscape in cancer: How cellular identity goes awry. Dev Cell 19: 698-711.
5. Datta J, Ghoshal K, Denny WA, Gamage SA, Brooke DG, Phiasivongsa P, Redkar S, Jacob ST. 2009. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res 69: 4277-4285.
6. Feinberg AP, Tycko B. 2004. The history of cancer epigenetics. Nat Rev Cancer 4: 143-153.
7. Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, Ropero S, Erkek E, Bozdogan O, Peinado H, Niveleau A, Mao JH, Balmain A, Cano A, Esteller M. 2004. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res 64: 5527-5534.
8. Garcia-Manero G, Fenaux P. 2011. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 29: 516-523.
9. Girault I, Tozlu S, Lidereau R, Bieche I. 2003. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 9: 4415-4422.
10. Gopalakrishnan S, Van Emburgh BO, Shan J, Su Z, Fields CR, Vieweg J, Hamazaki T, Schwartz PH, Terada N, Robertson KD. 2009. A novel DNMT3B splice variant expressed in tumor and pluripotent cells modulates genomic DNA methylation patterns and displays altered DNA binding. Mol Cancer Res 7: 1622-1634.
11. Hanigan CL, Van Engeland M, De Bruine AP, Wouters KA, Weijenberg MP, Eshleman JR, Herman JG. 2008. An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. Gastroenterology 135: 1654-1664. e2.
12. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. 1994. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 91: 709-713.
13. Ibrahim AE, Arends MJ, Silva AL, Wyllie AH, Greger L, Ito Y, Vowler SL, Huang TH, Tavaré S, Murrell A, Brenton JD. 2010. Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. Gut 60: 499-508.
14. Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H. 2010. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 116: 3830-3834.
15. Jeltsch A. 2006. Molecular enzymology of mammalian DNA methyltransferases. Curr Top Microbiol Immunol 301: 203-225.
16. Jones PA, Taylor SM. 1980. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20: 85-93.
17. Jones PA, Baylin SB. 2007. The epigenomics of cancer. Cell 128: 683-692.
18. Jones JS, Amos CI, Pande M, Gu X, Chen J, Campos IM, Wei Q, Rodriguez-Bigas M, Lynch PM, Frazier ML. 2006. DNMT3b polymorphism and hereditary nonpolyposis colorectal cancer age of onset. Cancer Epidemiol Biomark Prev 15: 886-891.
19. Kuck D, Caulfield T, Lyko F, Medina-Franco JL. 2010. Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther 9: 3015-3023.
20. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, Schmidt H, Zhang Q, Osborne JR, Lin L, O'Laughlin M, McMichael JF, Delehaunty KD, McGrath SD, Fulton LA, Magrini VJ, Vickery TL, Hundal J, Cook LL, Conyers JJ, Swift GW, Reed JP, Alldredge PA, Wylie T, Walker J, Kalicki J, Watson MA, Heath S, Shannon WD, Varghese N, Nagarajan R, Westervelt P, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Wilson RK. 2010. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363: 2424-2433.
21. Liang G, Chan MF, Tomigahara Y, Tsai YC, Gonzales FA, Li E, Laird PW, Jones PA. 2002. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol 22: 480-491.
22. Lin H, Yamada Y, Nguyen S, Linhart H, Jackson-Grusby L, Meissner A, Meletis K, Lo G, Jaenisch R. 2006. Suppression of intestinal neoplasia by deletion of Dnmt3b. Mol Cell Biol 26: 2976-2983.
23. Linhart HG, Lin H, Yamada Y, Moran E, Steine EJ, Gokhale S, Lo G, Cantu E, Ehrich M, He T, Meissner A, Jaenisch R. 2007. Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev 21: 3110-3122.
24. López de Silanes I, Gorospe M, Taniguchi H, Abdelmohsen K, Srikantan S, Alaminos M, Berdasco M, Urdinguio RG, Fraga MF, Jacinto FV, Esteller M. 2009. The RNA-binding protein HuR regulates DNA methylation through stabilization of DNMT3b mRNA. Nucleic Acids Res 37: 2658-2671.
25. Lübbert M, Müller-Tidow C, Hofmann WK, Koeffler HP. 2008. Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapy. J Cell Biochem 104: 2059-2070.
26. Okano M, Bell DW, Haber DA, Li E. 1999. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247-257.
27. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B. 2002. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416: 552-556.
28. Rius M, Stresemann C, Keller D, Brom M, Schirrmacher E, Keppler D, Lyko F. 2009. Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation. Mol Cancer Ther 8: 225-231.
29. Robertson KD. 2001. DNA methylation, methyltransferases, and cancer. Oncogene 20: 3139-3155.
30. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, Jones PA. 1999. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: Coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 27: 2291-2298.
31. Rodriguez-Paredes M, Esteller M. 2011. Cancer epigenetics reaches mainstream oncology. Nat Med 17: 330-339.
32. Roll JD, Rivenbark AG, Jones WD, Coleman WB. 2008. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Cancer 7: 15.
33. Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M, Caballero R, Alaminos M, Setien F, Paz MF, Herranz M, Palacios J, Arango D, Orntoft TF, Aaltonen LA, Schwartz S, Jr., Esteller M. 2006. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 38: 566-569.
34. Schaefer M, Lyko F. 2010. Solving the Dnmt2 enigma. Chromosoma 119: 35-40.
35. Shah MY, Vasanthakumar A, Barnes NY, Figueroa ME, Kamp A, Hendrick C, Ostler KR, Davis EM, Lin S, Anastasi J, Le Beau MM, Moskowitz IP, Melnick A, Pytel P, Godley LA. 2010. DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Res 70: 5840-5850.
36. Shen H, Wang L, Spitz MR, Hong WK, Mao L, Wei Q. 2002. A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res 62: 4992-4995.
37. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. 2010. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28: 605-613.
38. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
39. Soejima K, Fang W, Rollins BJ. 2003. DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras. Oncogene 22: 4723-4733.
40. Yang X, Lay F, Han H, Jones PA. 2010. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 31: 536-546.